Amy Comstock Rick, the new director of strategic coalitions for the FDA's Rare Disease Innovation Hub

November 4, 2024 03:14 PM EST

Rare disease biopharma companies weigh in on FDA's new innovation hub

Zachary Brennan

Senior Editor

AstraZeneca’s Alexion, BridgeBio, BioMarin, Ultragenyx and others, including Sen. Bob Casey (D-PA), recently weighed in on the details of a new cross-cutting FDA collaboration hub …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rare disease biopharma companies weigh in on FDA's new innovation hub

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Rare dis­ease bio­phar­ma com­pa­nies weigh in on FDA's new in­no­va­tion hub

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Rare disease biopharma companies weigh in on FDA's new innovation hub